Tomorrow, the FDA is scheduled to review Cell Theraputics’ drug Pixantrone (brand name is “Pixuvri”) for the treatment of non-Hodgkin’s lymphoma.  According to the company, patients treated with the drug in a Phase III trial attained a high rate of remissions compared to those patients treated with normal chemotherapy.  Last month, however, the FDA raised questions regarding the safety of the drug.  Adding to this are the recent lawsuits pending on the company in regards to the company’s directors and officers issuing materially false and misleading statements.  The next 30 days are going to be interesting, and I am still holding on to my shares of CTIC, despite the fact that it is a huge risk.  To let you know where I currently stand, I also have shares in GNVC, DDSS, and BCLI.  I’ve noticed a favorite of mine, SPEX, has retreated all the way back down to 1.40, and I think with another .05-.10 drop, I will be looking to scoop up some shares.